Definitive Healthcare Shares Rise 13% After Advent International Submits Acquisition Proposal
Shares of Definitive Healthcare Corp. (NASDAQ:DH) surged 13% on Wednesday, following the submission of a non-binding proposal by Advent International to acquire the company's outstanding shares and units not already owned by the firm. The proposed acquisition price of $1.02 per share represents a significant premium to Definitive Healthcare's recent trading price, sparking investor interest and speculation about the potential outcome of the proposal.
Advent International's Proposal: Key Details
According to a letter dated September 1, 2026, Advent International submitted a proposal to acquire all outstanding shares of Class A common stock and Definitive OpCo Units not already owned by the firm or its affiliate, Jason Krantz, the company's founder and Executive Chairman. The proposal assumes that Krantz would roll over his shares and units into the equity of the surviving company, should the acquisition be completed.
Advent International emphasized that its proposal is non-binding and does not represent a definitive agreement. The company stated that it would not proceed with the proposed acquisition without the approval of Definitive Healthcare's Special Committee, which consists of disinterested and independent directors. The Special Committee has the authority to evaluate, negotiate, or reject the potential transaction and will receive advice from independent legal and financial advisers as it considers the proposal.
Background and Context
Definitive Healthcare is a healthcare technology company that provides data and analytics solutions to healthcare organizations. The company has experienced significant growth in recent years, driven by its innovative products and expanding customer base. Advent International, a global private equity firm, has been a longtime investor in Definitive Healthcare, demonstrating its confidence in the company's business model and growth prospects.
The proposed acquisition price of $1.02 per share represents a 36% premium to Definitive Healthcare's 60-day volume-weighted average daily trading price of $0.75 per share as of August 31, 2026. This premium suggests that Advent International is willing to pay a significant premium to acquire the company, which could be a positive indicator for Definitive Healthcare's value and growth potential.
Implications and Next Steps
The proposed acquisition by Advent International has significant implications for Definitive Healthcare's shareholders, employees, and customers. If the acquisition is completed, it could lead to a change in the company's leadership, strategy, and direction. The Special Committee's evaluation and consideration of the proposal will be closely watched by investors and stakeholders, as it will determine the outcome of the potential transaction.
Definitive Healthcare's board of directors has appointed Clay Ritchey as the company's next Chief Executive Officer and a member of the board, effective September 8, 2026. Ritchey will succeed Kevin Coop, who departed as Chief Executive Officer and a board member on August 31, 2026. The circumstances surrounding Coop's departure are not clear, and it remains to be seen how the transition will impact the company's operations and performance.
What to Watch Next
The proposed acquisition by Advent International remains subject to consideration by the Special Committee and the negotiation and execution of definitive transaction documents. Investors and stakeholders will be closely watching the developments surrounding the proposal, including the Special Committee's evaluation and any updates on the potential transaction. The outcome of the proposal will have significant implications for Definitive Healthcare's future direction and growth prospects.
As the situation unfolds, ChainPulse will provide updates and analysis on the proposed acquisition and its potential impact on Definitive Healthcare and its stakeholders.